Retatrutide results in the clinical trials.

A plain guide to reading trial results

Retatrutide results from clinical trials show some of the largest weight reductions documented for any drug in obesity research. The headline figure — a mean -24.2% body-weight change over 48 weeks at the highest Phase 2 dose — comes from a randomized, double-blind, placebo-controlled Phase 2 trial, the most rigorous type of human study design. Understanding what that means in plain terms: participants in the trial were randomly assigned to either the compound or a placebo (a dummy injection) without knowing which they received, and neither did the researchers assessing outcomes. The -24.2% is the mean across all participants in that dose group; individual results varied.

Phase 2 results are proof-of-concept, not proof of approval. They demonstrate that the compound produces a measurable effect in the enrolled population — they do not establish long-term safety, cardiovascular outcomes, or durability. That is the explicit purpose of Phase 3. The results below are the best available published evidence; they come from populations under close clinical monitoring with scheduled safety assessments — not from unmonitored research use.

Body weight results — Phase 2 obesity trial (48 weeks)

The 48-week Phase 2 obesity trial (338 adults, once-weekly subcutaneous injection) produced the following mean body-weight changes versus placebo by dose group ^[1]:

• 1 mg: -8.7% vs -2.1% placebo
• 4 mg: -17.3% vs -2.1% placebo
• 8 mg: -22.8% vs -2.1% placebo
• 12 mg: -24.2% vs -2.1% placebo

In the 12 mg group, 63% of participants achieved at least 20% total body weight loss by week 48 ^[12]. Mean systolic blood pressure was reduced by 8.79 mmHg ^[12].

A 2025 systematic review and meta-analysis pooling three RCTs (878 participants across obesity and diabetes populations) found a pooled mean weight difference of -14.33% versus placebo ^[8]. The meta-analysis found no statistically significant difference in overall adverse event rates between retatrutide and placebo (RR 1.11, P=0.24).

A 2025 review in Biomolecules characterizes this weight-loss magnitude as a step-change versus prior incretin-class therapies and frames it alongside bariatric surgery benchmarks ^[6]. The Cell review (2024) synthesizes the pharmacological basis for up to ~20-30% weight loss through triple agonism ^[9].

Blood sugar results — Phase 2 type 2 diabetes trial (36 weeks)

In a separate 36-week Phase 2 trial (281 adults with type 2 diabetes), retatrutide 12 mg produced ^[2]:

• HbA1c reduction: -2.02% (vs -0.01% placebo at 24 weeks)
• Body weight reduction: -16.94% (vs -3.00% placebo at 36 weeks)
• GI adverse events (mild-to-moderate): 35% of participants
• Severe hypoglycemia: none reported
• Deaths: none attributed to retatrutide

Participants on background insulin required dose reductions during the trial, consistent with the compound's GLP-1- and GIP-mediated augmentation of insulin secretion.

A 2026 review in Cardiology in Review synthesizes the cardiovascular-kidney-metabolic implications of Phase 2 outcomes, highlighting the 24.2% body weight loss, 63% achieving ≥20% TBW loss, and HbA1c reduction of 2.02% in T2D ^[12]. The review also notes a systemic blood pressure reduction of 8.79 mmHg and significant UACR attenuation.

Liver fat results — MASLD Phase 2a substudy (48 weeks)

A Phase 2a substudy (98 participants with obesity or overweight and MASLD, ≥10% liver fat by MRI-PDFF, no type 2 diabetes) produced relative liver-fat changes at 24 weeks ^[5]:

• 1 mg: -42.9%
• 4 mg: -57.0%
• 8 mg: -81.4%
• 12 mg: -82.4% (vs +0.3% placebo)

At 12 mg, 86% of participants achieved normal liver fat (<5%) by week 24; reductions were sustained at 48 weeks (-86.0% at 12 mg). A 2026 mechanistic review in Frontiers in Medicine describes the hepatic lipid metabolism regulation, anti-inflammatory, and fibrosis-modulating mechanisms underlying these outcomes ^[15].

Kidney marker results

A post-hoc analysis across both Phase 2 trials found ^[7]:

• UACR reduction ~37% (12 mg, type 2 diabetes group vs placebo)
• UACR reduction ~28-31% (8-12 mg, obesity group vs placebo)
• eGFR increase 5.3-8.5 mL/min/1.73m2 (obesity group)

The authors characterize the renal-safety signal as favorable. Phase 2 excluded participants with eGFR <45. The dedicated TRANSCEND-CKD outcomes trial is ongoing and will provide data on patients with significant renal impairment.

Phase 1b results — first human pharmacokinetics (12 weeks)

The Phase 1b trial (72 adults with type 2 diabetes, 12 weeks) established the pharmacokinetic foundation for all subsequent trial designs ^[4]:

• Half-life: approximately 6 days — supports once-weekly dosing
• Placebo-adjusted weight loss at highest dose: -8.96 kg (90% CI -11.16 to -6.75) over 12 weeks
• Daily glucose reduction: -2.8 mmol/L at 3 mg
• Treatment-emergent adverse events: 63% (mostly GI, acceptable safety profile per authors)

See the full discussion of retatrutide results and comparative data on the retatrutide vs tirzepatide page.

What Phase 3 results will add

The TRIUMPH Phase 3 program is designed to answer what Phase 2 cannot: long-term safety over two-plus years; cardiovascular outcomes (MACE — major adverse cardiovascular events); renal outcomes in patients with CKD; durability of weight loss after treatment discontinuation; and head-to-head data versus tirzepatide as an active comparator. Phase 2 results demonstrated efficacy; Phase 3 results will determine whether that efficacy profile meets the regulatory standard for approval and whether long-term benefits outweigh long-term risks. Results are expected in 2026-2027 for several trial arms.